Cerebrospinal fluid amyloid beta 42, total tau, and phosphorylated tau 181 are well accepted markers of Alzheimer’s disease. These biomarkers better reflect disease pathogenesis compared to clinical diagnosis. Identifying genes/loci that regulate the levels of these biomarkers can help us uncover novel biological pathways involved in the disease mechanism. We performed a GWAS meta-analysis including 18,948 individuals of European ancestry from 30 different cohorts, including the Knight-ADRC, ADNI, DIAN, ALFA+, EADB among others. This is the largest study to date for the three CSF biomarkers.